BloodScan Biotech Inc., founded in 2023, is a biotechnology company focused on innovating and applying liquid biopsy technology. Established and technology-transferred by a research team from the University of Michigan, the company aims to set a new global standard in the field of liquid biopsy, with the primary goal of overcoming cancer.
The company’s core technology, Labyrinth One—Automated CTC Enrichment System, features innovative designs that significantly enhance the purity, efficiency, and viability of CTC extraction from blood samples. This advancement has a profound impact on cancer diagnosis, monitoring, and personalized medicine, with the potential to achieve breakthrough progress in cancer care.
BloodScan Biotech's mission is to integrate industry, academia, and research efforts to drive improvements throughout the entire cancer diagnosis and treatment cycle using cutting-edge technology, ultimately aiming to transform cancer care.

BloodScan Biotech Inc.

Org chart

Teams

Offices